Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results-Reference-Cited by-同舟云学术

Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results

Published:2019-08 Issue: Volume:154 Page:13-20
ISSN:0920-1211
Container-title:Epilepsy Research
language:en
Short-container-title:Epilepsy Research

Author:

Laux Linda C.,Bebin E. Martina,Checketts Daniel,Chez Michael,Flamini Robert,Marsh Eric D.,Miller Ian,Nichol Kathryn,Park Yong,Segal Eric,Seltzer Laurie,Szaflarski Jerzy P.,Thiele Elizabeth A.,Weinstock Arie

Funder

GW Pharmaceuticals

Epilepsy Therapy Project of the Epilepsy Foundation

State of Alabama General Funds

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology

Reference10 articles.

1. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial;Devinsky;Lancet Neurol.,2016

2. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome;Devinsky;N. Engl. J. Med.,2017

3. Effect of Cannabidiol on drop seizures in the lennox-gastaut syndrome;Devinsky;N. Engl. J. Med.,2018